Trinity Biotech (TRIB) Operating Income (2009 - 2024)

Trinity Biotech (TRIB) has reported Operating Income for 16 consecutive years, with -$11.5 million the latest figure, recorded in Q4 2024.

• Quarterly Operating Income fell 204.66% year-over-year to -$11.5 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$21.2 million (up 21.76% YoY) and the FY2025 annual result came in at -$15.8 million, up 25.4% from the prior year.
• Operating Income declined to -$11.5 million in Q4 2024 per TRIB's latest filing, from -$2.6 million in the prior quarter.
• Over the last five years, Operating Income for TRIB reached as high as $9.1 million in Q3 2020 and fell as low as -$14.9 million in Q2 2023.
• A 5-year average of -$2.0 million and a median of -$2.2 million in 2022 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2020 — Operating Income jumped 581.55% — and 2022, when it tumbled 1548.85%.
• Year by year, Operating Income stood at $9.1 million in 2020, then tumbled by 93.79% to $563000.0 in 2021, then slumped by 1548.85% to -$8.2 million in 2022, then surged by 53.67% to -$3.8 million in 2023, then plunged by 204.66% to -$11.5 million in 2024.
• According to Business Quant data, Operating Income over the past three periods registered -$11.5 million, -$2.6 million, and -$4.1 million for Q4 2024, Q3 2024, and Q2 2024 respectively.